Skip Navigation

European Heart Journal 1988 9(5):462-470;
Copyright © 1988 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by FACCHINI, M.
Right arrow Articles by SCHWARTZ, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FACCHINI, M.
Right arrow Articles by SCHWARTZ, P. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1988 The European Society of Cardiology

Multiple comparison of several antiarrhythmic agents by acute oral drug testing in patients with chronic ventricular arrhythmias

M. FACCHINI, O. BONAZZI, S. G. PRIORI, T. VARISCO, G. ZUANETTI and P. J. SCHWARTZ

Unità di Studio delle Aritmie, Centro di Fisiologia Clinica e Ipertensione, Istituto di Clinica Medica Generale e Terapia Medica, Università degli Studi di Milano Milan, Italy

Received 16 June 1987; revised 5 October 1987; .

Address for correspondence: Peter J. Schwartz, M.D., Clinica Medica Generale—-Pad. Sacco, Via F Sforza 35, 20123 Milano, Italy.

Abstract

This study addresses the question of the choice of treatment for the individual patient with chronic ventricular arrhythmias. Acute oral drug testing offers a pragmatic approach to the rapid selection of the drug with the best efficacy/side-effect ratio by allowing multiple comparisons within the same patient. Forty patients with chronic ventricular arrhythmias received a single oral dose of the following antiarrhythmic drugs: flecainide 200 mg, propafenone 450 mg, disopyramide 300 mg, mexiletine 400 mg, tocainide 800 mg, verapamil 160 mg, propranolol 120 mg. Criteria for efficacy were suppression of complex ventricular arrhythmias and a > 90% reduction in premature ventricular beats lasting for at least 2 h.

An antiarrhythmic effect was achieved with each of the drugs in the following percentages of patients: flecainide 69·;4%, propafenone 67·5%, disopyramide 54·;8%, mexiletine 45·2%, tocainide 31·;3%, verapamil 31·3%, propranolol 12·5%. In no case was worsening of arrhythmia observed. At the end of the acute testing phase, the drug that had proved most effective in each patient was administered at a full dosage for 72 h. A concordant response between the two phases was observed in 80% of patients and was as high as 89% when the analysis was limited to flecainide and propafenone.

This study shows the feasibility and practical advantages for patient management of a multiple comparison of antiarrhythmic drugs by acute oral drug testing. It also provides, in a non-invasive cost-effective manner, unique insights into the complex relationship between drug characteristics, individual responses and clinical efficacy.

Key Words: Acute oral drug testing • ventricular arrhythmias


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.